Product Information
ESCITALOPRAM 20 MG TABLET is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.0632 per EA under NDC 82009003710. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Sep 11, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009003710
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ESCITALOPRAM OXALATEApproval Type
Generic (ANDA)
FDA Application
ANDA090939FDA Approved
9/11/2012
TE Code
AB
On Market Since
3/1/2023
Pharmacological Classes
Price Statistics
The NADAC for ESCITALOPRAM 20 MG TABLET has been published 178 times since May 10, 2023, and over the history we have for it it has declined 27.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0632 per EA |
|---|---|
| All-time high | $0.0892 (Feb 14, 2024) |
| All-time low | $0.0548 (Nov 20, 2024) |
| 52-week high | $0.0717 |
| 52-week low | $0.0605 |
| Median price | $0.0758 |
| Average price | $0.0731 |
| Largest weekly change | -29.2% (Nov 20, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the escitalopram oxalate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
escitalopram oxalate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ESCITALOPRAM 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ESCITALOPRAM 20 MG TABLET, manufactured by Quallent Pharmaceuticals Health LLC, is $0.0632 per EA (NDC 82009003710), effective Sep 30, 2026.
How has the price of ESCITALOPRAM 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for ESCITALOPRAM 20 MG TABLET has declined 27.4%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for ESCITALOPRAM 20 MG TABLET?
Since May 10, 2023, the NADAC for ESCITALOPRAM 20 MG TABLET has ranged from a low of $0.0548 (Nov 20, 2024) to a high of $0.0892 (Feb 14, 2024), with a median of $0.0758 per EA.
Are there cheaper alternatives to ESCITALOPRAM 20 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ESCITALOPRAM 20 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ESCITALOPRAM 20 MG TABLET?
ESCITALOPRAM 20 MG TABLET (NDC 82009003710) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.